clinical trial · NCT05808634
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
Advanced AdenocarcinomaBA3182
brief summary
The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma
started
Jul 14, 2023
primary completion
Sep 15, 2028
completion
Sep 15, 2028
last updated
Sep 25, 2025
detailed description
This is a multi-center, open-label, Phase 1 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3182 in patients with advanced adenocarcinoma.
official title
An Open-label, Multicenter, Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, a Bispecific Epithelial Cell Adhesion Molecule (EpCAM)/CD3 Antibody, in Patients With Advanced Adenocarcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol